Compare BIO-TECHNE Corp (TECH) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs iShares TIPS Bond ETF — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while iShares TIPS Bond ETF trades at $106.82. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while iShares TIPS Bond ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| TECH | TIP | |
|---|---|---|
Market Cap | $11.34B | — |
Sector | Health | Fixed Income |
52-Week High | $72.48 | $112.20 |
52-Week Low | $43.31 | $106.77 |
Enterprise Value | $11.36B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
TIP trades at $107.05 with minimal daily movement (+0.07%), showing stability amid broader market volatility. Technical indicators signal a bearish trend with moving averages and overall momentum favoring sellers. The company has announced upcoming dividends totaling $1.84 per share for H2-2026, providing income appeal. Recent news highlights Treasury market volatility and inflation concerns that may impact bond-related equities.
The stock faces headwinds from bearish technical momentum and macroeconomic uncertainty around interest rates. Dividend payments offer some support, but limited fundamental data availability requires careful monitoring of upcoming financial disclosures for clearer valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
